LNTEF yields 4.03% · JNJ yields 2.13%● Live data
📍 LNTEF pulled ahead of the other in Year 1
Combined, LNTEF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of LNTEF + JNJ for your $10,000?
LINTEC Corporation develops, manufactures, and sells adhesive-related products in Japan and internationally. It operates through three segments: Printing and Industrial Materials Products, Electronic and Optical Products, and Paper and Converted Products. The Printing and Industrial Materials Products segment offers adhesive products for seals and labels, labeling machines, automobile-use adhesive products, and industrial-use adhesive tapes; window, marking, and automotive films; barcode label supplies and printers, digital label printing machines, films for outdoor signs and advertising, and interior finishing mounting films. The Electronic and Optical Products segment provides semiconductor-related adhesive tapes and equipment, multilayer ceramic capacitor related tapes, and optical display-related adhesive products. The Paper and Converted Products segment offers color papers for envelopes, colored construction papers, special function papers, high-grade printing papers, high-grade papers for paper products, release papers for adhesive products, release films for optical-related products, casting papers for synthetic leather, and casting papers for carbon fiber composite materials. The company was formerly known as FSK Corporation and changed its name to LINTEC Corporation in April 1990. The company was founded in 1927 and is headquartered in Tokyo, Japan.
Full LNTEF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.